New Leqembi Data Support Efficacy and Safety of Subcutaneous Autoinjector
BioArctic's partner Eisai presented new data at an Alzheimer's conference demonstrating that Leqembi's subcutaneous formulation matches the efficacy and safety of intravenous administration.
Stockholm-based BioArctic AB announced today that its partner Eisai has presented new clinical data for the Leqembi® (lecanemab) subcutaneous autoinjector (SC-AI) formulation. The data were presented at the Alzheimer’s Association International Conference (AAIC®) in London, held July 12-15, 2026.
The study demonstrated that Leqembi administered via subcutaneous injections offers patients with early Alzheimer's disease a comparable efficacy and safety profile to the drug's current intravenous (IV) administration form. These findings support a fully subcutaneous treatment pathway from initiation through maintenance, aiming to increase patient convenience and flexibility.
Potentially, this development could reduce hospital visits and facilitate home-based patient care by avoiding the need for intravenous administration in a clinical setting. Eisai's ongoing development of such dosing formulations is intended to simplify clinical treatment for patients.